Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) primarily used to manage nerve damage caused by diabetes. Because it dissolves in fat rather than water, benfotiamine delivers dramatically more thiamine to your bloodstream than standard supplements. A pharmacokinetic study found that oral benfotiamine produced roughly 11 times higher thiamine levels in plasma compared to the same dose of regular thiamine hydrochloride. That superior absorption is the reason benfotiamine appears in supplements targeting diabetic complications, nerve pain, and, more recently, cognitive decline.
How Benfotiamine Differs From Regular Thiamine
Standard thiamine (vitamin B1) is water-soluble, which limits how much your body can absorb from a single dose. Excess amounts pass through your kidneys and into your urine. Benfotiamine sidesteps that bottleneck. Its fat-soluble structure lets it cross cell membranes more easily, and once inside the body it converts into the same active form of thiamine your cells already use: thiamine diphosphate.
Beyond just raising thiamine levels higher, benfotiamine appears to do things regular thiamine cannot do as effectively. It is more potent at reducing oxidative stress and preventing the cellular damage that high blood sugar causes. This distinction matters most for people with diabetes, where chronically elevated glucose triggers a cascade of harmful biochemical pathways.
Diabetic Nerve Damage
The most studied use of benfotiamine is for diabetic peripheral neuropathy, the tingling, burning, and numbness that develops in the hands and feet when sustained high blood sugar injures small nerve fibers. Several clinical trials have tested whether benfotiamine can relieve these symptoms, with mixed but generally encouraging short-term results.
In the BEDIP trial, 40 patients with diabetic neuropathy took 400 mg of benfotiamine daily for three weeks. By the end, a composite score measuring pain, muscle strength, sensory function, coordination, and reflexes improved significantly compared to placebo. A larger trial called BENDIP enrolled 165 patients for six weeks and found that the higher dose (600 mg per day) led to significant symptom improvement in patients who completed the protocol, though the overall group analysis narrowly missed statistical significance.
Longer studies have been less convincing. A 12-month trial (the BOND study) found only a trend toward symptom improvement with benfotiamine, without reaching statistical significance. And a 24-month study in people with type 1 diabetes found no measurable changes in peripheral nerve function. The pattern suggests benfotiamine may help with symptom relief in the short term, particularly at higher doses, but its ability to reverse or halt the underlying nerve damage over time remains unproven.
How It Works Against High Blood Sugar Damage
Chronically elevated blood sugar generates harmful byproducts called advanced glycation end-products, or AGEs. These sticky molecules damage blood vessels, nerves, and organs. In diabetes, three major biochemical pathways drive this damage: the hexosamine pathway, the AGE formation pathway, and the protein kinase C pathway. All three become overactive when excess sugar floods your cells.
Benfotiamine blocks all three. It does this by boosting the activity of an enzyme called transketolase, which reroutes the sugar byproducts that would otherwise feed those damaging pathways. Instead of building up as AGEs or activating inflammatory signals, the excess molecules get shunted into a safer metabolic route. This is the core mechanism behind nearly every proposed benefit of benfotiamine: it helps your cells handle sugar overload without accumulating damage.
Blood Vessel Protection After Meals
One of the more striking findings comes from a small study in 13 people with type 2 diabetes. Researchers gave them a meal high in AGEs (the kind produced by high-heat cooking) and measured blood vessel function over the following six hours. Without treatment, the meal caused a 60 percent drop in small-vessel blood flow within two hours and a 35 percent impairment of large-vessel dilation within four hours. Blood markers of oxidative stress and inflammation also spiked.
After just three days of benfotiamine at 1,050 mg per day, the same meal produced none of those effects. Blood vessel function was completely preserved, and the inflammatory markers stayed flat. This suggests benfotiamine could protect against the vascular damage that accumulates meal by meal in people with poorly controlled blood sugar.
Cognitive Decline and Alzheimer’s Disease
A newer area of interest is whether benfotiamine can slow cognitive decline. The brain is heavily dependent on glucose metabolism, and disrupted glucose processing is a recognized feature of Alzheimer’s disease. Since benfotiamine normalizes how cells use glucose, researchers have tested whether it could help preserve brain function.
A Phase 2 trial enrolled 71 people with mild cognitive impairment or early Alzheimer’s (all with confirmed amyloid plaques on brain scans) and gave them 600 mg of benfotiamine or placebo daily for one year. The trial missed its primary goal: the benfotiamine group showed 43 percent slower cognitive decline on the main test, but the difference was not statistically significant. However, one secondary measure of overall dementia severity showed a 77 percent slower decline, which was significant. An exploratory analysis also suggested improved brain glucose utilization on PET scans.
Blood tests in the trial confirmed that benfotiamine increased thiamine levels 161-fold and significantly reduced levels of abnormally glycated fats and proteins, indicating it was normalizing glucose metabolism. These results are promising enough to justify larger trials, but benfotiamine is not an established treatment for Alzheimer’s.
Kidney Disease in Diabetes
Animal studies suggested benfotiamine might protect the kidneys from diabetes-related damage, particularly by reducing albumin leaking into the urine (a hallmark of early diabetic kidney disease). A randomized trial tested this in 82 people with type 2 diabetes who already had mildly elevated albumin in their urine despite being on standard blood pressure medications. Participants took 900 mg of benfotiamine daily or placebo for 12 weeks.
The result was disappointing. While benfotiamine successfully raised thiamine levels, it did not significantly reduce albumin excretion or a marker of kidney tubule damage. The researchers noted that benfotiamine might be more useful in earlier stages of kidney disease, before significant damage has occurred, but that remains speculative.
Dosages Used in Research
There is no officially established dose for benfotiamine, but clinical trials provide a range. Most studies have used between 300 and 600 mg per day, with some short-term trials going as high as 900 to 1,050 mg daily. The neuropathy research suggests 600 mg per day (split into two doses) may be more effective than 300 mg for symptom relief.
Benfotiamine has been well tolerated across studies lasting up to 24 months. Safety monitoring in long-term trials found no changes outside normal reference ranges for standard blood tests. One notable finding: a 24-month study observed a small but statistically significant increase in diastolic blood pressure in the benfotiamine group compared to placebo. The clinical importance of this is unclear, but it is worth being aware of if you have blood pressure concerns. Benfotiamine supplements are widely available over the counter and are not regulated as a pharmaceutical in most countries.